Treating cancer's kinase 'addiction'

被引：52

作者：

Baselga, J

Arribas, J

机构：

[1] Vall Hebron Res Inst, Med Oncol Res Program, Barcelona 08035, Spain

[2] Vall Hebron Univ Hosp, Barcelona 08035, Spain

来源：

NATURE MEDICINE | 2004年 / 10卷 / 08期

关键词：

D O I：

10.1038/nm0804-786

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

When the tyrosine kinase inhibitor imatinib (Gleevec) was found to induce high remission rates in patients with chronic myeloid leukemia, this was hailed as a success for targeted tumor therapy. Since then, the repertoire of cancer types that respond to such inhibitors has expanded and researchers are beginning to grapple with the problem of acquired drug resistance. The activating kinase mutations targeted by these drugs can be viewed as the Achilles heel of cancer - they promote malignant progression, yet can turn cancer into a therapeutically exploitable disease.

引用

收藏

页码：786 / 787

页数：2

相关论文

共 27 条

[1] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[2] Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? [J].

Arteaga, CL ;

Baselga, J .

CANCER CELL, 2004, 5 (06) :525-531

[3] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].

Azam, M ;

Latek, RR ;

Daley, GQ .

CELL, 2003, 112 (06) :831-843

[4]

Buchdunger E, 1996, CANCER RES, V56, P100

[5]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[6] SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS [J].

BUCHDUNGER, E ;

ZIMMERMANN, J ;

METT, H ;

MEYER, T ;

MULLER, M ;

REGENASS, U ;

LYDON, NB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2558-2562

[7] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[8] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[9]

Demetri GD, 2004, P AN M AM SOC CLIN, V23, P195

[10] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042